Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.

Abstract: The present invention relates to a method for decellularization of porcine stomach mucosal tissue for culturing stomach tissue or stomach cancer tissue, a composition for producing a scaffold, and a method for culturing tissue, and particularly, to: a method for decellularization of porcine stomach mucosal tissue comprising chopping porcine stomach mucosal tissue and performing first treatment, second treatment, washing, and third treatment; a decellularization product composed of porcine stomach mucosal tissue decellularized by the method; a composition for producing a stomach tissue or stomach cancer tissue culture scaffold containing a pepsin digest of the decellularization product; and a method for culturing stomach tissue or stomach cancer tissue comprising adding stomach cells or stomach cancer cells to the composition, followed by shaping to produce a tissue culture scaffold containing stomach cells or stomach cancer cells, and incubating the scaffold in a medium.

Abstract: The present invention relates to a preparation method of a composition for culturing pancreatic organoids, a composition thereby, and an organoid culture method using the same. The present invention is capable of creating an environment that is more similar to an actual tissue than a conventional Matrigel-based culture system, and in particular, exhibits an effect of facilitating tissue differentiation in pancreatic organoid culture and effectively developing into a form that is similar to an actual tissue.

Abstract: The present invention relates to a preparation method of a composition for culturing lung organoids, a composition thereby, and an organoid culture method using the same. The present invention is capable of creating an environment that is more similar to an actual tissue than a conventional Matrigel-based culture system, and in particular, exhibits an effect of facilitating tissue differentiation in lung organoid culture and effectively developing into a form that is similar to an actual tissue.

Abstract: An embodiment of the present disclosure provides an extracellular matrix-based bioadhesive as an adhesive in the form of a composition including an extracellular matrix-containing hydrogel and a gelatin curing agent, wherein the extracellular matrix-containing hydrogel is gelatinized. Since the extracellular matrix-based bioadhesive according to an embodiment of the present disclosure has the same or similar rheological properties as gelatin, the bioadhesive has flowability at a temperature of 30° C. or higher and may be evenly and easily applied to a lesion site in the body. In addition, the extracellular matrix-based bioadhesive according to an embodiment of the present disclosure may adhere well to the lesion site because of a level of adhesive strength that is about 2 to 6 times higher than that of fibrin glue used as a commercial tissue adhesive.

Abstract: Disclosed are an artificial esophageal structure having a multi-layer structure using three-dimensional bio-printing, and a manufacturing device and manufacturing method therefor. The artificial esophageal structure having a multi-layer structure according to one embodiment of the present invention comprises: a first layer in the shape of a hollow column and having a circular cross section; a second layer which is disposed inside the first layer and which is a column structure that simulates the mucosal layer of the esophagus; and an interlayer support part which is disposed between the first layer and the second layer and which maintains a gap between the layers, wherein the first layer and second layer each comprise: a plurality of column parts disposed at predetermined intervals; and a plurality of strands formed between the plurality of column parts by a dragging technique, and may have a porous structure due to pores between the plurality of strands.

Abstract: A modified extracellular matrix-based hydrogel according to an example of the present disclosure includes an extracellular matrix-denatured collagen conjugate formed by a Michael addition reaction between an extracellular matrix having an amine group and a denatured collagen into which an ethylenically unsaturated bond functional group is introduced. The modified extracellular matrix-based hydrogel according to the present disclosure exhibits enhanced mechanical properties (e.g., viscoelasticity) compared to the extracellular matrix hydrogel before modification. In addition, it shows a high cell viability when the bioink is prepared by encapsulating cells in a modified extracellular matrix-based hydrogel according to the present disclosure.

Abstract: The present invention relates to a method for generating semi-mature dendritic cells by treating immature dendritic cells with the auto-antigen, cytokine, and PGE2 as a target for the treatment of autoimmune diseases, particularly rheumatoid arthritis, in which the levels of NR4A2 and/or UBASH3B at gene or protein are increased more than 2-fold compared to the immature dendritic cells In addition, the present invention relates to a cell therapeutic agent for treating or preventing autoimmune diseases, containing the semi-mature dendritic cells as an active ingredient. The present invention increases the therapeutic efficacy on rheumatoid arthritis retaining responsiveness to the same auto-antigen that being used for preparing semi-mature dendritic cells, thereby enabling cell therapy.

Abstract: Provided is a three-dimensional printing composition including decellularized extracellular matrix; and riboflavin as a crosslinking agent. A three-dimensional structure having high mechanical strength can be prepared by performing a printing process using the three-dimensional printing composition according to the present invention and a layer-by-layer process through crosslinking under UVA light to prepare a three-dimensional structure configuration; and then performing thermal gelation of the three-dimensional structure configuration. Further provided is a method for preparing said three-dimensional printing composition and a method for preparing a three-dimensional structure using said three-dimensional printing composition.

Abstract: The present invention relates to a method for generating semi-mature dendritic cells by treating immature dendritic cells with the auto-antigen, cytokine, and PGE2 as a target for the treatment of autoimmune diseases, particularly rheumatoid arthritis, in which the levels of NR4A2 and/or UBASH3B at gene or protein are increased more than 2-fold compared to the immature dendritic cells In addition, the present invention relates to a cell therapeutic agent for treating or preventing autoimmune diseases, containing the semi-mature dendritic cells as an active ingredient. The present invention increases the therapeutic efficacy on rheumatoid arthritis retaining responsiveness to the same auto-antigen that being used for preparing semi-mature dendritic cells, thereby enabling cell therapy.

Abstract: The present invention relates to novel uses of the MLN 51 gene or protein. The MLN 51 gene and protein is closely related to the development of rheumatoid arthritis and serve as biomarker and therapeutic target for rheumatoid arthritis, particularly chronic synovitis.

Abstract: The present invention relates to novel uses of the MLN 51 gene or protein. The MLN 51 gene and protein is closely related to the development of rheumatoid arthritis, particularly chronic synovitis.